A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC is a phase 2 interventional study registered as NCT07521852 by TaiRx, Inc., with 40 participants planned, started 2026-03-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: CVM-1118 + Sintilimab + TACE. Conditions listed: HCC - Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.